Compare RES & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | ODTX |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1995 | 2025 |
| Metric | RES | ODTX |
|---|---|---|
| Price | $5.86 | $24.26 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.64 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 205.2K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $41,919,000,000.00 | N/A |
| Revenue This Year | $3.29 | N/A |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $98.83 | ★ N/A |
| Revenue Growth | ★ 2216.21 | N/A |
| 52 Week Low | $4.18 | $15.10 |
| 52 Week High | $8.16 | $29.05 |
| Indicator | RES | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.85 | 52.24 |
| Support Level | $5.44 | $22.89 |
| Resistance Level | $5.86 | $28.53 |
| Average True Range (ATR) | 0.20 | 2.20 |
| MACD | -0.09 | -0.47 |
| Stochastic Oscillator | 1.12 | 35.81 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. Its operating segment includes Technical Services and Support Services. The Technical Services segment, which generates maximum revenue, comprises service lines that generate revenue based on equipment, personnel, or materials at the well site and are closely aligned with completion and production activities of the customers. The Support Services segment comprises service lines that generate revenue from services and equipment offered off the well site and are closely aligned with the customers' drilling activities.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.